Literature DB >> 2532633

Modulation of immune response against tumor cells by the in vivo administration of an autoreactive Th clone.

M Kubo1, K Sano, I Fujisawa, Y Asano, T Tada.   

Abstract

The immunization of C3H mice with irradiated syngeneic MM48 tumor cells induced specific tumor-neutralizing cells (TNC). The TNC activity was mediated by the L3T4+, Ly-2- T cell population, and the generation of TNC coincided with the appearance of delayed-type hypersensitivity response against MM48 antigen. The administration of an auto-I-Ak reactive T helper cell clone MS202 to normal C3H mice resulted in the facilitation of growth of MM48 tumor due to the induction of T suppressor (Ts) cells. Splenic T cells from animals given this T cell clone inhibited the TNC activity of immunized mice resulting in the escape of MM48 from the TNC effect. The surface phenotype of the Ts cells was L3T4+, Ly-2-. The Ts cells induced by the clone MS202 were totally antigen-nonspecific, and were able to suppress both the effector and inductive processes of TNC. The results suggest the presence of a physiological MHC-restricted T cell circuit that regulates immune responses against the growing tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532633      PMCID: PMC5917916          DOI: 10.1111/j.1349-7006.1989.tb02266.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


cytotoxic T cells delayed‐type hypersensitivity intradermally intraperitoneal intravenously monoclonal antibody major histocompatibility complex mouse immunoglobulin T helper tumor‐neutralizing cells T suppressor
  18 in total

1.  Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts.

Authors:  H J WINN
Journal:  J Immunol       Date:  1961-02       Impact factor: 5.422

2.  Evidence for in vivo protection against murine-sarcoma virus-induced tumors by T lymphocytes from immune animals.

Authors:  R M Gorczynski
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

3.  Regulatory circuits and antibody responses.

Authors:  L A Herzenberg; S J Black; L A Herzenberg
Journal:  Eur J Immunol       Date:  1980-01       Impact factor: 5.532

Review 4.  The murine sarcoma virus-induced tumor: exception or general model in tumor immunology?

Authors:  J P Levy; J C Leclerc
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

5.  T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.

Authors:  J C Leclerc; H Cantor
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

6.  Mouse lymphocytes with and without surface immunoglobulin: preparative scale separation in polystyrene tissue culture dishes coated with specifically purified anti-immunoglobulin.

Authors:  M G Mage; L L McHugh; T L Rothstein
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

7.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.

Authors:  H Nakajima; H Fujiwara; Y Takai; Y Izumi; S Sano; T Tsuchida; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

8.  The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

Authors:  H Fujiwara; M Fukuzawa; T Yoshioka; H Nakajima; T Hamaoka
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

9.  Cell-mediated immune reaction against tumors induced by oncornaviruses. II. Nature of the effector cells in tumor-cell cytolysis.

Authors:  J C Leclerc; E Gomard; F Plata; J P Levy
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

10.  Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.

Authors:  P D Greenberg; D E Kern; M A Cheever
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.